[The evaluation of the gastroprotective effect of sucralfate in Helicobacter pylori-associated gastric ulcer].
The purpose of the investigation was to study the effects of sucralfate on the biochemical composition as well as the anti-radicals and antioxidative activity (ARA; AOA) of the gastric supra-epithelial mucosal layer (GSEML) in patients with Helicobacter pylori (HP)-associated gastric ulcer (GU). A hundred patients suffering from HP-associated GU were examined. The biochemical composition as well as the ARA and AOA of the GSEML were studied before and after eradication therapy as well as after additional administration of sucralfate. Biochemical and chemoluminescence techniques were used. All the patients with HP-associated GU displayed significant changes in all the mentioned parameters vs. healthy persons, which consisted in the secretion of premature glycoproteins and elevated ARA and AOA of the native gastric mucus. Effective antisecretory and eradication therapy by triple regimen recommended by Maastricht consensus-2 (2000), with ulcerous defect scarring, did not normalize the biochemical composition of the GSEML. Additional administration of sucralfate led to positive changes in ARA and AOA, as well as the biochemical composition of the GSEML.
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000627:therapeutic use*; D005260:Female; D005609:Free Radicals / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000382:microbiology; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D008163:Luminescent Measurements; D008297:Male; D008875:Middle Aged; D013276:Stomach Ulcer / Q000188:drug therapy* / Q000382:microbiology*; D013392:Sucralfate / Q000627:therapeutic use*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D000975:Antioxidants; D005609:Free Radicals; D013392:Sucralfate